STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) to participate in 2023 Jefferies London Healthcare Conference, with Tim Power, VP of investor relations, addressing questions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
-
News

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Rhea-AI Summary
Bristol Myers Squibb (BMY) announces that the FDA has accepted the sBLA for Breyanzi to expand its indication to include treatment for adult patients with relapsed or refractory CLL or SLL. The FDA has granted the application Priority Review and assigned a PDUFA goal date of March 14, 2024. The application is based on results from the TRANSCEND CLL 004 study, which demonstrated deep and durable efficacy of Breyanzi. If approved, it would be the first and only CAR T cell therapy available for this patient population, addressing a critical unmet need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.83%
Tags
none
-
News

Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches

Rhea-AI Summary
Tempus (NYSE: TMPS) announces strategic research collaboration with Bristol Myers Squibb to accelerate cancer research and treatment options using AI, multimodal datasets, and patient-derived disease models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
AI
News

Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023

Rhea-AI Summary
Bristol Myers Squibb will present new clinical trial data and real-world analyses of CAMZYOS® (mavacamten) at the American Heart Association's annual Scientific Sessions. The data includes new analyses of the effectiveness of CAMZYOS in patients with and without gene variants, as well as real-world analyses of patients with symptomatic obstructive hypertrophic cardiomyopathy receiving CAMZYOS in clinical practice. The Bristol Myers Squibb-Pfizer Alliance will also present data on oral anticoagulant utilization patterns among patients with non-valvular atrial fibrillation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
conferences
-
News

Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) will present research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Results from 73 data disclosures, including 22 oral presentations, will be featured, showcasing their commitment to transformative medicines for blood disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
News

Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference

Rhea-AI Summary
Bristol Myers Squibb (BMY) will participate in the 2023 UBS BioPharma Conference in Miami Beach, Florida, on November 8, 2023. Lynelle Hoch, president of the cell therapy organization, will answer questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
News

Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) appoints Boerner as CEO, Caforio to retire as Chair after 23 years
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
management
-
News

Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) has priced a public offering of senior unsecured notes in a combined aggregate principal amount of $4.5 billion. The notes will be issued in four tranches with varying interest rates and maturity dates. The offering is expected to close on November 13, 2023. The net proceeds will be used for general corporate purposes, including the financing of the proposed acquisition of Mirati Therapeutics, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

Rhea-AI Summary
Karyopharm Therapeutics has entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the combination of mezigdomide and selinexor in patients with relapsed/refractory multiple myeloma. The trial will assess the combination in patients who have prior exposure to certain drug agents and have received at least two prior lines of therapy. The trial is expected to be initiated in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
clinical trial
News

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Rhea-AI Summary
Bristol Myers Squibb's type II variation application for Opdivo in combination with cisplatin-based chemotherapy for the treatment of urothelial carcinoma has been validated by the EMA. The application is based on the Phase 3 CheckMate -901 trial, which showed statistically significant and clinically meaningful survival benefit over standard-of-care cisplatin-based chemotherapy. Opdivo and Opdivo-based combinations have demonstrated improvements in overall survival in Phase 3 clinical trials across multiple tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none

FAQ

What is the current stock price of Bristol-Myers Squibb Co (BMY)?

The current stock price of Bristol-Myers Squibb Co (BMY) is $57.88 as of February 24, 2025.

What is the market cap of Bristol-Myers Squibb Co (BMY)?

The market cap of Bristol-Myers Squibb Co (BMY) is approximately 116.2B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Stock BMY logo
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

#rank Ranked by Market Cap
#rank Ranked by Dividends

BMY Stock Data

116.18B
2.02B
0.12%
78.52%
1.36%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON